- Research article
- Open Access
- Open Peer Review
B7-H4gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population
© Zhang et al; licensee BioMed Central Ltd. 2009
- Received: 05 June 2009
- Accepted: 11 November 2009
- Published: 11 November 2009
B7-H4, a co-inhibitory molecule of the B7 family, can restrain T cell proliferation, cytokine secretion and the development of cytotoxicity. B7-H4 is expressed in tumor tissues at a higher level than in normal tissues, and has a potential effect to protect tumors from anti-tumor immune responses. This case-control study was carried out to determine the potential influences of B7-H4 gene polymorphisms on the susceptibility and progression of breast cancer in Han women of Northeast China.
We genotyped three B7-H4 variants (rs10754339, rs10801935 and rs3738414) and tagged all common haplotypes (frequency greater than or equal to 1%) in a Chinese population consisting of 500 breast cancer cases and 504 control individuals matched for age. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to determine the genotypes.
Our data indicated that, compared with the common genotype and allele of each SNP, the rs10754339 AG genotype and G allele showed a significantly increased risk of breast cancer (OR = 1.455, 95% CI 1.119-1.892; OR = 1.325, 95% CI 1.073-1.637, respectively). The rs10801935 CC genotype, the rs3738414 AA genotype and the rs3738414 A allele were associated with a significantly decreased risk of breast cancer (OR = 0.328, 95% CI 0.145-0.739; OR = 0.412, 95% CI 0.203-0.835; OR = 0.698, 95% CI 0.564-0.864, respectively). Additionally, the rs10754339 GG genotype was significantly associated with lymph node metastasis and PR status, and the G allele and the AG genotype were respectively associated with lymph node metastasis and ER status. In haplotype analysis, we observed that compared with the AAG haplotype, the AAA haplotype showed a significantly decreased risk of breast cancer (OR = 0.689, 95% CI 0.539-0.881), but the GAG haplotype was associated with a significantly increased risk of breast cancer (OR = 1.511, 95% CI 1.125-2.031). And the AAA and the GCG haplotypes also respectively have significant influences on tumor size and ER status.
These results suggest that B7-H4 gene polymorphism may contribute to the sporadic breast cancer risk and prognosis in Chinese Han women.
- Breast Cancer
- Breast Cancer Risk
- Progesterone Receptor Status
- Sporadic Breast Cancer
Breast cancer is one of the most common malignant tumors in females, and its etiology as well as prognosis is extremely complex. The immune system, which plays an important role of immune surveillance in finding and eliminating cancer cells, can influence the development and growth of breast cancer. The central regulator of anti-tumor immune response is mediated by T lymphocyte, whose activation is regulated by co-stimulatory molecules, especially the receptors and ligands in B7-CD28 family [1, 2].
B7-H4 is a recently identified member of B7 family, and conducts a co-inhibitory signal to T cell activation, which can restrain T cell proliferation, cytokine secretion and the development of cytotoxicity [3–5]. Experiments in vitro show that B7-H4 inhibits T cell activation through restraining IL-2 production and arresting cell cycles of both CD4+ and CD8+ T cell, and experiments in vivo also support the function of B7-H4 as an inhibitor to T cell mediated immunity [3–5]. B7-H4 mRNA transcriptions are detected extensively in spleen, lung, thymus and other normal tissues, but the proteins are not detectable in these tissues . In contrast, high levels of B7-H4 protein are expressed in most kinds of tumors, such as breast cancer [6, 7], ovarian cancer [7, 8], lung cancer [8, 9] and renal cell carcinoma . Previous reports [6, 7, 11] showed that the high expression of B7-H4 protein in breast cancer decreased the number of tumor infiltrating lymphocytes (TILs) and prevented tumor cells from apoptosis. Therefore, the B7-H4 protein is a negative regulator of the anti-tumor immune response and may play an important role in breast cancer. And in our research, we investigated the association between B7-H4 gene polymorphisms and the risk of breast cancer.
The human B7-H4 gene is located on chromosome 1p11.1, and consists of six exons and five introns . There are two types of B7-H4 mRNA transcriptions which are ~2.0 kb and ~800 bp. The larger transcription is dominant, and differs from the small one that has part of 3'-untranslating region (UTR) spliced. It is likely that the difference of 3'-UTR between the two transcripts affects the efficiency of B7-H4 protein synthesis . In addition, B7-H4 mRNA transcription is inconsistent with its protein expression , indicating that B7-H4 expression is tightly controlled at the translational level in peripheral tissues. It has been pointed out that UTRs and introns, especially intron1, can modulate gene expression at many levels, such as the production of stable mRNA, the translational efficiency, the rate of mRNA decay, and so on [12–14]. In our study, we detected three polymorphic sites in UTRs and intron1, and established the association between B7-H4 gene polymorphisms and the risk of breast cancer in a Chinese Han population of Northeast China.
Clinicopathologic features of breast cancer cases (n = 500)
No. of cases (%)
Tumor size (cm)
TZ ≤ 2
2<TZ ≤ 5
SNP selection and genotype analysis
Using Pupasview software , we found that rs10754339 in 3'-UTR, and rs3738414 in 5'-UTR are located on exonic splicing enhancers (ESEs), which may influence splicing of the primary transcript with production of stable mRNAs . We also found that rs10801935 in intron1 may cause the alteration of the pre-mRNA secondary structure as predicted by RNAstructure 4.5 software . Therefore, we detected these three potential functional single nuclear polymorphisms (SNPs) (rs10754339, rs10801935 and rs3738414) to investigate their relevance to breast cancer in a Chinese Han population of Northeast China.
Genomic DNA was extracted from 5 ml frozen whole blood with the Universal Genomic DNA Extraction Kit Ver. 3.0 (TaKaRa, Japan), following the manufacturer's protocol. Then, through a PCR-RFLP assay, we determined the dimorphism of rs10754339, rs10801935 and rs3738414. The desired fragment was amplified by PCR with a Biometra T-Gradient Thermoblock (Biometra, Göttingen, Germany) in a reaction mixture of 25 μl solution containing 0.3 μg of genomic DNA template, 1.25 U of Taq DNA polymerase with 10×PCR buffer (Mg2+ plus) and dNTPs contained in the kit (TaKaRa, Japan), and 0.1 μl of each primer (Invitrogen, China). PCR products were digested with restriction enzymes (NEB, UK) according to the manufacturer's description, and were analyzed with 2.0% agarose gel electrophoresis. Primer sequences of each SNPs were rs10754339 (F: 5'-TCCTATGGGTCTGTCAATG-3'; R: 5'-GCTGCTAAACTCAAAGGC-3'), rs10801935 (F: 5'-TAGTGGCGGTACAATAGC-3'; R: 5'-AGTGCCTCTGTTTCTTCC-3'), and rs3738414 (F: 5'-AAAGACCTCACTGCTGTTCC-3'; R: 5'-CCACAGTCAGGAGGAAAGTC-3'). Annealing temperatures were rs10754339 (53.2°C), rs10801935 (55.6°C), and rs3738414 (55.6°C). The lengths of PCR products were rs10754339 (341 bp), rs10801935 (466 bp), and rs3738414 (419 bp). And restriction enzymes were rs10754339 (MscI), rs10801935 (SalI), and rs3738414 (BtsI) (please refer to additional file 1). In order to ensure quality control of genotyping results, we randomly selected 10% of the samples to direct sequencing, and the results were consistent with the PCR-RFLP results.
Hardy-Weinberg equilibrium (HWE) was tested using the genotyping results of cases and controls respectively. The polymorphisms were excluded if they deviated from HWE (P < 0.05), as well as if the minor allele frequency was less than 5% or the missing data was more than 25%. The frequencies of allele and genotype were obtained by a simple counting. Haploview 3.2 was used to reset haplotypes and evaluate the frequencies in this case-control study. Chi-square test was adopted using SPSS 13.0 software in order to compare the different distributions within the allele, genotype and haplotype frequencies in cases and controls respectively, and the threshold for significance was P < 0.05. 10,000 permutations were run by Haploview program to measure the P-value of allele frequencies after the correction for multiple-testing bias. An odds ratio (OR) and its 95% confidence interval (CI) were calculated using SPSS 13.0 software to estimate the relative risk associated with rare alleles for breast cancer.
Genotype and allele frequencies
Genotype frequencies of B7-H4 polymorphisms in cases and controls
Cases (n = 500)
Controls (n = 504)
Allele counts and frequencies of B7-H4 polymorphisms in cases and controls
Cases (n = 500)
Controls (n = 504)
In addition, we analyzed the correlation between the polymorphisms of B7-H4 gene and a series of clinicopathologic features, including lymph node metastasis, tumor size, and the statuses of estrogen receptor (ER) and progesterone receptor (PR). It was observed that in rs10754339, compared with the AA genotypes, the GG genotype was associated with a significantly increased risk of lymph node metastasis (OR = 2.492, 95% CI 1.054-5.894, P = 0.033), and the G allele showed a significantly increased risk of lymph node metastasis compared with the A allele (OR = 1.394, 95% CI 1.045-1.860, P = 0.024). Compared with the rs10754339 AA genotype, the AG genotype was associated with a significantly increased expression of ER (OR = 1.640 95% CI 1.092-2.464, P = 0.017), and the GG genotype was associated with a decreased expression of PR (OR = 0.367 95% CI 0.135-0.994, P = 0.041). However, no obvious correlation was revealed between the genotype and allele frequencies and tumor size.
B7-H4 haplotype frequencies in cases and controls
cases (n = 500)
controls (n = 504)
OR (95% CI)
We also analyzed the association between the haplotypes and the clinical features of cases. We found that the AAA haplotype was significantly associated with tumor size (P = 0.020), and compared with the AAG haplotype, the GCG haplotype frequency was associated with a significantly increased expression of ER (OR = 1.903, 95% CI 1.034-3.502, P = 0.036). However, no significant association was obtained between haplotypes and either the lymph node metastasis or the statuses of PR.
Breast cancer is one of the polygenetic disorders with complex inheritance patterns. Recently, the determination of genetic polymorphisms provided a new approach to investigate the etiology of such complex genetic diseases . Reports indicate that breast cancer susceptibility and prediction can be influenced by the polymorphism of cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene, which encodes a classic molecule offering a co-inhibitory signal to T cell activation . Additionally, some other genes encoding novel co-inhibitors, such as PD-1 and B and T lymphocyte attenuator (BTLA), are attractive in case-control studies, as candidate genes between the gene polymorphisms and the risk of diseases [20, 21]. As another co-inhibitory molecule investigated more recently, B7-H4 has shown a potential effect on tumors, by which tumors may escape from an anti-tumor immune response. To elaborate, B7-H4 protein is over expressed in several malignant tumors while is little expressed in normal tissues [6–8, 10], and its high expression in breast cancer decreased the number of TILs and prevented tumor cells from undergoing apoptosis [6, 7, 11].
In our case-control study, we chose three potentially functional polymorphisms of B7-H4, rs10754339, rs10801935 and re3738414, and firstly detected their association with the risk and prognosis of breast cancer in Chinese Han women. The results indicate that some of the alleles, genotypes and haplotypes of these three SNPs are associated with the risk and prognosis of breast cancer, which will be discussed below respectively. According to our results, in rs10754339, women with the AG genotype and G allele are likely to have an increased risk of breast cancer (OR = 1.455, 95% CI 1.119-1.892; OR = 1.325, 95%CI 1.073-1.637, respectively), indicating that the rs10754339 G allele maybe plays a risk role in breast cancer. It has been suggested that B7-H4 mRNA is widely distributed in lymphoid and nonlymphoid tissues. However, the protein is rarely expressed in normal tissues but highly expressed in many kinds of tumor tissues including breast cancer [3, 6–10]. Also, 3'-UTR can regulate gene expression at many different levels, and cis-acting elements of 3'-UTR mediate the stability, degradation, and subcellular localization of mRNA [12, 22]. Therefore, rs10754339 located on ESE may regulate the production of mRNA molecules through above mechanism, and G allele may be associated with an increased expression of B7-H4 and then influence the susceptibility of breast cancer. In addition, most tissues contain two types of B7-H4 transcriptions which are ~2.0 kb and ~800 bp. The larger one is major and their difference is that the small one has 3'-UTR spliced out partly . Rs10754339 may also be involved in the formation and expression of different types of B7-H4 transcriptions.
In rs10801935, women with the CC genotype are likely to have a decreased risk of breast cancer (OR = 0.328, 95% CI 0.145-0.739), indicating that the rs10801935 CC genotype in intron 1 may be a protective factor in breast cancer. As we know, human gene expression requires transcription controls mediated by the presence of intron sequences, especially, the first intron, which contains various regulatory elements and splicing control elements [14, 23]. Mutations occurring in introns can induce the aberrant splicing due to the disruption of the splice site, the splicing enhancers and silencers, or the alteration of the pre-mRNA secondary structure, which results in translational prevention [16, 24, 25]. Supposed to change the secondary structure of pre-mRNA, rs10801935 can possibly influence B7-H4 translational efficiency by causing deviant splicing, and CC genotype may down-regulate the B7-H4 expression and decrease the breast cancer risk.
Our research also suggests that women with the AA genotype and the A allele in rs3738414 are less likely to have breast cancer (OR = 0.412, 95% CI 0.203-0.835; OR = 0.698, 95% CI 0.564-0.864, respectively), indicating that the A allele of rs3738414 may have a potentially protective effect on breast cancer. 5'-UTR, upon which a number of DNA binding sites of regulatory factors exist, is important for post-transcriptional modification and translation efficiency . Using Pupasview software , the rs3738414 is supposed to be located on ESE, and the mutation of rs3738414 perhaps changes the protein binding pattern, and further affects the B7-H4 expression. Consequently, rs3738414 A allele may reduce the B7-H4 expression and decrease the susceptibility of breast cancer.
In addition, according to the analysis for the association between B7-H4 gene polymorphisms and clinical presentations, we found that the rs10754339 GG genotype was significantly associated with lymph node metastasis and PR status, and the G allele and the AG genotype were respectively associated with lymph node metastasis and ER status. However, the other two SNPs in our study were found to be irrelevant to clinicopathologic features. Lymph node involvement, ER and PR status are important in predicting the long-term survival of breast cancer cases. Lymph node metastasis positive cases have higher mortality , and steroid hormone receptors are valuable as predictive markers of endocrine therapy . Therefore, rs10754339 may be significant to forecast the prognosis of breast cancer.
The association between B7-H4 gene and breast cancer was further confirmed by the analysis of haplotype. Results suggested that the AAA haplotype showed a significantly decreased risk of breast cancer, whereas GAG haplotype had a contrary outcome (OR = 0.689, 95% CI 0.539-0.881; OR = 1.511, 95% CI 1.125-2.031). To elaborate, the AAA haplotype appears to be a protective factor in breast cancer, but the GAG haplotype may be a risk factor in breast cancer. Furthermore, we found that both AAA and GCG haplotypes had significantly correlations with the clinical presentations. These haplotypes may also be the valuable prognostic factors for survival of breast cancer cases.
It was observed in our study that polymorphisms of the B7-H4 gene may affect the individual breast cancer risk and prognosis in Chinese Han women, which provides the first evidence for the involvement of the human B7-H4 gene in breast cancer. The variants of rs10754339, rs10801935 and rs3738414 are probably involved in the risk of breast cancer. Furthermore, rs10754339 may participate in the prognosis of breast cancer. AAA and GAG haplotypes probably influence on the breast cancer risk, and AAA and GCG may participate in the progression of breast cancer. However, studies focusing on new polymorphisms with more samples from other populations as well as the investigation of the basic functions of B7-H4 gene mutations remain to be further conducted.
This study was supported by a grant from the Science Foundation of Heilongjiang province, China (GB05C402-03) and a grant from Heilongjiang health bureau (2009-026). We thank all patients and healthy volunteers for providing blood samples. We are grateful to the participating hospitals for their collaboration.
- Inman BA, Frigola X, Dong H, Kwon ED: Costimulation, coinhibition and cancer. Curr Cancer Drug Targets. 2007, 7 (1): 15-30. 10.2174/156800907780006878.View ArticlePubMedGoogle Scholar
- Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004, 4 (5): 336-347. 10.1038/nri1349.View ArticlePubMedGoogle Scholar
- Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003, 18 (6): 849-861. 10.1016/S1074-7613(03)00152-3.View ArticlePubMedGoogle Scholar
- Prasad DVR, Richards S, Mai XM, Dong C: B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003, 18 (6): 863-873. 10.1016/S1074-7613(03)00147-X.View ArticlePubMedGoogle Scholar
- Zang XX, Loke P, Kim J, Murphy K, Waitz R, Allison JP: B7x: A widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (18): 10388-10392. 10.1073/pnas.1434299100.View ArticlePubMedPubMed CentralGoogle Scholar
- Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005, 11 (5): 1842-1848. 10.1158/1078-0432.CCR-04-1658.View ArticlePubMedGoogle Scholar
- Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J: The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005, 306 (1): 128-141. 10.1016/j.yexcr.2005.01.018.View ArticlePubMedGoogle Scholar
- Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L: Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003, 171 (9): 4650-4654.View ArticlePubMedGoogle Scholar
- Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006, 53 (2): 143-151. 10.1016/j.lungcan.2006.05.012.View ArticlePubMedGoogle Scholar
- Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA. 2006, 103 (27): 10391-10396. 10.1073/pnas.0600937103.View ArticlePubMedPubMed CentralGoogle Scholar
- Mugler KC, Singh M, Tringler B, Torkko KC, Liu W, Papkoff J, Shroyer KR: B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol. 2007, 15 (4): 363-370. 10.1097/01.pai.0000213159.79557.71.View ArticlePubMedGoogle Scholar
- Mignone F, Gissi C, Liuni S, Pesole G: Untranslated regions of mRNAs. Genome Biol. 2002, 3 (3): REVIEWS0004-10.1186/gb-2002-3-3-reviews0004.View ArticlePubMedPubMed CentralGoogle Scholar
- Nott A, Meislin SH, Moore MJ: A quantitative analysis of intron effects on mammalian gene expression. RNA. 2003, 9 (5): 607-617. 10.1261/rna.5250403.View ArticlePubMedPubMed CentralGoogle Scholar
- Gazave E, Marques-Bonet T, Fernando O, Charlesworth B, Navarro A: Patterns and rates of intron divergence between humans and chimpanzees. Genome Biol. 2007, 8 (2): R21-10.1186/gb-2007-8-2-r21.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma H, Hu Z, Wang H, Jin G, Wang Y, Sun W, Chen D, Tian T, Jin L, Wei Q, et al: ERCC6/CSB gene polymorphisms and lung cancer risk. Cancer Lett. 2009, 273 (1): 172-176. 10.1016/j.canlet.2008.08.002.View ArticlePubMedGoogle Scholar
- Baralle D, Baralle M: Splicing in action: assessing disease causing sequence changes. J Med Genet. 2005, 42 (10): 737-748. 10.1136/jmg.2004.029538.View ArticlePubMedPubMed CentralGoogle Scholar
- Mathews DH, Turner DH, Zuker M: RNA secondary structure prediction. Curr Protoc Nucleic Acid Chem. 2007, Chapter 11 (Unit 11): 12-Google Scholar
- Shastry BS: SNP alleles in human disease and evolution. J Hum Genet. 2002, 47 (11): 561-566. 10.1007/s100380200086.View ArticlePubMedGoogle Scholar
- Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Dehaghani AS: Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat. 2004, 86 (1): 1-7. 10.1023/B:BREA.0000032918.89120.8e.View ArticlePubMedGoogle Scholar
- Lee SH, Lee YA, Woo DH, Song R, Park EK, Ryu MH, Kim YH, Kim KS, Hong SJ, Yoo MC, et al: Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther. 2006, 8 (6): R163-10.1186/ar2071.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin SC, Kuo CC, Chan CH: Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. J Biomed Sci. 2006, 13 (6): 853-860. 10.1007/s11373-006-9113-7.View ArticlePubMedGoogle Scholar
- Chen JM, Ferec C, Cooper DN: A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet. 2006, 120 (1): 1-21. 10.1007/s00439-006-0180-7.View ArticlePubMedGoogle Scholar
- Majewski J, Ott J: Distribution and characterization of regulatory elements in the human genome. Genome Res. 2002, 12 (12): 1827-1836. 10.1101/gr.606402.View ArticlePubMedPubMed CentralGoogle Scholar
- Braddock M, Muckenthaler M, White MR, Thorburn AM, Sommerville J, Kingsman AJ, Kingsman SM: Intron-less RNA injected into the nucleus of Xenopus oocytes accesses a regulated translation control pathway. Nucleic Acids Res. 1994, 22 (24): 5255-5264. 10.1093/nar/22.24.5255.View ArticlePubMedPubMed CentralGoogle Scholar
- Balvay L, Libri D, Fiszman MY: Pre-mRNA secondary structure and the regulation of splicing. Bioessays. 1993, 15 (3): 165-169. 10.1002/bies.950150304.View ArticlePubMedGoogle Scholar
- Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW: An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008, 107 (3): 309-330. 10.1007/s10549-007-9556-1.View ArticlePubMedGoogle Scholar
- Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007, 25 (30): 4772-4778. 10.1200/JCO.2007.12.2747.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/394/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.